<SEC-DOCUMENT>0001140361-26-007148.txt : 20260227
<SEC-HEADER>0001140361-26-007148.hdr.sgml : 20260227
<ACCEPTANCE-DATETIME>20260227161554
ACCESSION NUMBER:		0001140361-26-007148
CONFORMED SUBMISSION TYPE:	SC14D9C
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260227
DATE AS OF CHANGE:		20260227

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LISATA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC14D9C
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-34343
		FILM NUMBER:		26700075

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-229-2590

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALADRIUS BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20170808

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LISATA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC14D9C

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-229-2590

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALADRIUS BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20170808

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC14D9C
<SEQUENCE>1
<FILENAME>ef20066670_sc14d9c.htm
<DESCRIPTION>SC14D9C
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center; font-size: 18pt; font-weight: bold;">SCHEDULE 14D-9</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Solicitation/Recommendation Statement</div>
    <div style="text-align: center; font-weight: bold;">Under Section 14(d)(4) of the Securities Exchange Act of 1934</div>
    <div><br>
    </div>
    <div style="text-align: center; font-size: 24pt; font-weight: bold;">LISATA THERAPEUTICS, INC.</div>
    <div style="text-align: center; font-weight: bold;">(Name of Subject Company)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-size: 24pt; font-weight: bold;">LISATA THERAPEUTICS, INC.</div>
    <div style="text-align: center; font-weight: bold;">(Name of Person Filing Statement)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Common Stock, par value $0.001 per share</div>
    <div style="text-align: center; font-weight: bold;">(Title of Class of Securities)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">128058302</div>
    <div style="text-align: center; font-weight: bold;">(CUSIP Number of Class of Securities)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">David J. Mazzo, Ph.D.</div>
    <div style="text-align: center; font-weight: bold;">Chief Executive Officer</div>
    <div style="text-align: center; font-weight: bold;">Lisata Therapeutics, Inc</div>
    <div style="text-align: center; font-weight: bold;">110 Allen Road, Second Floor</div>
    <div style="text-align: center; font-weight: bold;">Basking Ridge, NJ 07920</div>
    <div style="text-align: center; font-weight: bold;">(908) 841-0100</div>
    <div style="text-align: center; font-weight: bold;">(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications</div>
    <div style="text-align: center; font-weight: bold;">on Behalf of the Person Filing Statement)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">With copies to:</div>
    <div style="text-align: center; font-weight: bold;">Jeffrey P. Schultz, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Ivan Presant, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Mintz Levin Cohn Ferris Glovsky &amp;</div>
    <div style="text-align: center; font-weight: bold;">Popeo, P.C.</div>
    <div style="text-align: center; font-weight: bold;">919 Third Avenue</div>
    <div style="text-align: center; font-weight: bold;">New York, NY 10022</div>
    <div style="text-align: center; font-weight: bold;">(212) 935-3000</div>
    <div>&#160;&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z783b99491531426ca9c3d68918976e17" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #000000;">Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>The information set forth under Items 1.01 and 9.01 of the Current Report on Form 8-K filed by Lisata Therapeutics, Inc. on February 27, 2026 (including all exhibits
      attached thereto and incorporated therein by reference) is incorporated herein by reference.</div>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
